---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-030546"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2024-07-01T23:59:59+00:00"
generated_at: "2026-06-01T00:03:28.428425+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ovid/Graviton announce positive Phase 1 data for OV888/GV101 CCM therapy; Phase 2 expected H2 2024

## Summary
- Phase 1 met primary safety/tolerability objectives: no serious adverse events at any dose.
- Headache was most common AE (23%); all mild and resolved within 24 hours.
- Target PK achieved: half-life ~12 hours supports once-daily dosing.
- Dose-dependent decrease in proinflammatory cytokines IL-17 and IL-21 confirms ROCK2 target engagement.
- Phase 2 proof-of-concept study in cerebral cavernous malformations planned for second half 2024.

## SEC filing metadata
- accession: 0001628280-24-030546
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2024-07-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828024030546/0001628280-24-030546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828024030546/ovid-20240701.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-030546
- JSON: https://secwatch.observer/filing/0001628280-24-030546.json
- Plain text: https://secwatch.observer/filing/0001628280-24-030546.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.